Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration.

Neurol Neuroimmunol Neuroinflamm

From the Synaptopathies and Autoantibodies (SynatAc) Team, Institut NeuroMyoGène-MeLiS, INSERM U1314/CNRS UMR 5284, Université de Lyon; French Reference Center on Paraneoplastic Neurological Syndrome, Hospices Civils de Lyon; University of Lyon, Université Claude Bernard Lyon 1; Department of Biopathology, Centre Leon Berard; INSERM 1052, CNRS 5286, Centre Leon Berard, Centre de Recherche en Cancérologie de Lyon; Cancer Genomics Platform, Department of Translational Research, Centre Leon Berard; Synergie Lyon Cancer- Bioinformatics Platform-Gilles Thomas, Centre de Recherche en Cancérologie de Lyon; and Laboratoire d'Immunothérapie des Cancers de Lyon (LICL), France.

Published: September 2022

AI Article Synopsis

  • Identified the role of genetic alterations in Yo antigens as a trigger for paraneoplastic cerebellar degeneration (PCD) in breast cancer, associated with the presence of anti-Yo antibodies.
  • Characterized 22 breast cancers with Yo-PCD, finding that they were typically aggressive, HER2-positive, and hormone receptor-negative with distinct genetic profiles.
  • Discovered significant immune responses in Yo-PCD breast cancers, including a high infiltration of immunoglobulin G-plasma cells and pathways linked to adaptive immunity, suggesting a specific cancer-related immune response.

Article Abstract

Background And Objectives: Paraneoplastic cerebellar degeneration (PCD) with anti-Yo antibodies is a cancer-related autoimmune disease directed against neural antigens expressed by tumor cells. A putative trigger of the immune tolerance breakdown is genetic alteration of Yo antigens. We aimed to identify the tumors' genetic and immune specificities involved in Yo-PCD pathogenesis.

Methods: Using clinicopathologic data, immunofluorescence (IF) imaging, and whole-transcriptome analysis, 22 breast cancers (BCs) associated with Yo-PCD were characterized in terms of oncologic characteristics, genetic alteration of Yo antigens, differential gene expression profiles, and morphofunctional specificities of their in situ antitumor immunity by comparing them with matched control BCs.

Results: Yo-PCD BCs were invasive carcinoma of no special type, which early metastasized to lymph nodes. They overexpressed human epidermal growth factor receptor 2 (HER2) but were hormone receptor negative. All Yo-PCD BCs carried at least 1 genetic alteration (variation or gain in copy number) on , encoding the main Yo antigen that was found aberrantly overexpressed in Yo-PCD BCs. Analysis of the differentially expressed genes found 615 upregulated and 54 downregulated genes in Yo-PCD BCs compared with HER2-driven control BCs without PCD. Ontology enrichment analysis found significantly upregulated adaptive immune response pathways in Yo-PCD BCs. IF imaging confirmed an intense immune infiltration with an overwhelming predominance of immunoglobulin G-plasma cells.

Discussion: These data confirm the role of genetic alterations of Yo antigens in triggering the immune tolerance breakdown but also outline a specific biomolecular profile in Yo-PCD BCs, suggesting a cancer-specific pathogenesis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278124PMC
http://dx.doi.org/10.1212/NXI.0000000000200015DOI Listing

Publication Analysis

Top Keywords

yo-pcd bcs
24
genetic alteration
12
paraneoplastic cerebellar
8
cerebellar degeneration
8
immune tolerance
8
tolerance breakdown
8
alteration antigens
8
yo-pcd
8
bcs
8
immune
6

Similar Publications

Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration.

Neurol Neuroimmunol Neuroinflamm

September 2022

From the Synaptopathies and Autoantibodies (SynatAc) Team, Institut NeuroMyoGène-MeLiS, INSERM U1314/CNRS UMR 5284, Université de Lyon; French Reference Center on Paraneoplastic Neurological Syndrome, Hospices Civils de Lyon; University of Lyon, Université Claude Bernard Lyon 1; Department of Biopathology, Centre Leon Berard; INSERM 1052, CNRS 5286, Centre Leon Berard, Centre de Recherche en Cancérologie de Lyon; Cancer Genomics Platform, Department of Translational Research, Centre Leon Berard; Synergie Lyon Cancer- Bioinformatics Platform-Gilles Thomas, Centre de Recherche en Cancérologie de Lyon; and Laboratoire d'Immunothérapie des Cancers de Lyon (LICL), France.

Article Synopsis
  • Identified the role of genetic alterations in Yo antigens as a trigger for paraneoplastic cerebellar degeneration (PCD) in breast cancer, associated with the presence of anti-Yo antibodies.
  • Characterized 22 breast cancers with Yo-PCD, finding that they were typically aggressive, HER2-positive, and hormone receptor-negative with distinct genetic profiles.
  • Discovered significant immune responses in Yo-PCD breast cancers, including a high infiltration of immunoglobulin G-plasma cells and pathways linked to adaptive immunity, suggesting a specific cancer-related immune response.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!